NextPoint: a new checkpoint target to extend immunotherapy’s reach

Cambridge, Mass.-based immunotherapy company NextPoint Therapeutics has identified a new checkpoint target that it believes can treat large numbers of patients who do not respond to PD-(L)1 therapy. The MPM Capital-founded biotech has raised $120 million in venture investment.

CEO Detlev Biniszkiewicz and CMO Leena Gandhi told BioCentury that NextPoint Therapeutics Inc. was created to leverage the biology, and advance the field’s understanding, of the B7 family of immune checkpoints, a group of about 10 proteins that includes B7-H1, more commonly known as PD-L1. ...